ТАРГЕТНАЯ ТЕРАПИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ (НОВЫЕ НАПРАВЛЕНИЯ)


Цитировать

Полный текст

Аннотация

Растущее понимание молекулярных явлений, происходящих при раке, привело к выявлению большого числа новых мишеней и параллельно к развитию множества новых методов противораковой терапии. Таргетная терапия сфокусирована на специфических молекулах в злокачественной клетке, включая ключевые молекулы, вовлеченные в процессы клеточной инвазии, метастазирования, апоптоза, контроля клеточного цикла и опухолевого ангиогенеза. Множество таргетных препаратов проходит испытания в клинических исследованиях. В данной статье представлены наиболее перспективные исследования новых таргетных средств и их комбинаций с традиционными цитостатиками.

Об авторах

Владимир Федорович Семиглазов

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

Гарик Альбертович Дашян

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

Владислав Владимирович Семиглазов

СПГМУ им. академика И.П. Павлова

СПГМУ им. академика И.П. Павлова

Руслан Маликович Палтуев

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

Алексей Георгиевич Манихас

СПбГУЗ Городской клинический онкологический диспансер, Санкт-Петербург

СПбГУЗ Городской клинический онкологический диспансер, Санкт-Петербург

Александр Алексеевич Бессонов

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

Анастасия Михайловна Ермаченкова

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

Дмитрий Евгеньевич Щедрин

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

Тенгиз Тенгизович Табагуа

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

Ирина Александровна Гречухина

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

Петр Владимирович Криворотько

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

Роман Владимирович Донских

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

Татьяна Юрьевна Семиглазова

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

Вера Витальевна Коларькова

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

ФГУ НИИ онкологии им. Н.Н. Петрова Минздравсоцразвития России

V F Semiglazo

G A Dashyan

V V Semiglazov

R M Paltuev

A G Manikhas

A A Bessonov

A M Yermachenkova

D Ye Schedrin

T T Tabagua

I A Grechukhina

P V Krivorotko

R V Donskih

T Yu Semiglazova

V V Kolarkova

Список литературы

  1. Anido J, Matar P, Albanell J, et al: ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2- overexpressing breast cancer cells. Clin Cancer Res 2003;9:1274-83.
  2. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;28:2445-59.
  3. Baselga J, Fumoleau P, Gil M, et al. Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: Preliminary results. J Clin Oncol 2004;22:14.
  4. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-302.
  5. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-37.
  6. Baselga J. Targeting the epidermal growth factor receptor: A clinical reality. J Clin Oncol 2001;19:41-4.
  7. Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-13.
  8. Carpenter JT, Roche H, Campone M, et al. Randomized 3-arm, phase II study of temsirolimus in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:16s.
  9. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2006;23:5314-22.
  10. Cheng JQ, Lindsley CW, Cheng GZ, et al. The Akt/PKB pathway: Molecular target for cancer drug discovery. Oncogene 2005;24:7482-92.
  11. Chow LSY, Jassem J, Baselga J, et al. Phase III study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006;97:abstr 6091.
  12. Chu I, Blackwell K, Chen S, et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005;65:18-25.
  13. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004;91:639-43.
  14. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
  15. Cristofanilli M, Boussen H, Ben Ayed F, et al. A phase II combination study of lapatinib and paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer. Breast Cancer Res Treat 2006;100:5.
  16. Cristofanilli M, Schiff R, Valero V, et al. Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib with placebo in combination with tamoxifen or anastrozole in hormone receptor- positive metastatic breast cancer. J Clin Oncol 2009;27:15.
  17. Dickler M. Phase II trial of erlotinib (OSI-774), and epidermal growth factor receptor (EGFR)- tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients with metastatic breast cancer. J Clin Oncol 2004;22:14s.
  18. Dickler MN, Cobleigh MA, Miller KD, et al. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2009;115:115-21.
  19. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001;61:131-37.
  20. Erlichman C, Hidalgo M. Boni JP, et al. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2006;24:2252-60.
  21. Frassoldati A, Guarneri V, Piacentini F, et al. Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: A double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/ LETLOB). Clin Breast Cancer 2008;8:97-100.
  22. Geyer CE, Foster J, Lindquist D, et al. Lapa- tinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;356:2733-43.
  23. Guix M, Granja Nde M, Meszoely I, et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancer. J Clin Oncol 2008;26:897-906.
  24. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the antiinsulin-like growth factor-l receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-40.
  25. Harris AL, Nicholson S, Sainsbury JR. et al. Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interaction with neu. J Steroid Biochem 1989;34:123-31.
  26. Hennessy ВТ, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
  27. Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer associated PI3KCA mutations are oncogenic in mammary epithelial cells. Cancer Res 2006;65:10992-11000.
  28. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46.
  29. Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced cancer. J Clin Oncol 2003;21:2492-99.
  30. Johnston SR, Semiglazov VF, Manikhas GM, et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat 2008;110:327-35.
  31. Jones HE, Gee JM, Hutcheson IR, et al. Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer 2006;13:S45-S51.
  32. Jones HE, Goddard L, Gee JM, et al. Insulinlike growth factor-l receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer. Endocr Relat Cancer 2004;11:793-814.
  33. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positieve, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-37.
  34. Kaur H, Silverman P, Singh D, et al. Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer. J Clin Oncol 2006;24:18s.
  35. Kiewe P, Hansmuller S, Kahlert S, et al. Phase I trial of the trifunctional anti-HER2 anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006;12:3085-91.
  36. Lane HA, Wood JM, McSheehy PM, et al. MTOR inhibitor RAD001 (Everolimus) has antiangio- genic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009;15:1612-22.
  37. Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy. Cancer Res 2009;68:5878-87.
  38. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2- positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90.
  39. Li T, Christos PJ, Sparano JA, et al. Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. Ann Oncol 2009;20:642-47.
  40. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases form HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-59.
  41. Meric-Bernstam F, Gonzale2-Angulo AM.Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009;27:2278-87.
  42. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
  43. Modi S, Beeram M, Krop IE, et al. A phase I study of trastuzumab-DM1, a first-in-class HER2- antibody drug conjugate, in patients with advanced HER2+ breast cancer. J Clin Oncol 2008;26:48s.
  44. Mom C, Eskens F, Gietema J, et al. Phase I study with BIBW 2992 an irreversible dual tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) in a 2 week on 2 week off schedule. J Clin Oncol 2006;24:18s.
  45. Nichoson Rl, Hutcheson IR, Knowlden JM, et al. Non endocrine pathways and endocrine resistance: Observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004;10:346S-54S.
  46. Nielsen TO, Hsu FD, Jensen K, et al. Immu- nohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
  47. O'Regan RM, Khuri FR. Farnesyl transferase inhibitors: The next targeted therapies for breast cancer? Endocr Relat Cancer 2004;11:191-205.
  48. O'Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008;26:44s.
  49. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin in patients with metastatic triple negative cancer: Results of a randomized phase II trial. J Clin Oncol 2009;27:18s.
  50. Perez EA, Koehler M, Byrne J, et al. Cardiac safety of lapatinib: Pooled analysis of 3,689 patients enrolled in clinical trials. Mayo Clinic Proc 2008;83:679-86.
  51. Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor- associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999;291:739-48.
  52. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-47.
  53. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
  54. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
  55. Sparano JA, Moulder S, Kazi A, et al. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: A phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J Clin Oncol 2006;24:3013-18.
  56. Takai Y, Sasaki T, Matozaki T: Small GTP- binding proteins. Physiol Rev 81:153-208, 2001
  57. Tanner B, Hasenclever D, Stern K, et al: ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 24:4317-4323, 2006
  58. Twelves C, Trigo JM, Jones R, et al. Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: A dose- escalation study. Eur J Cancer 2008;44:419-26.
  59. van Golen KL, Davies S, Wu ZF, et al. A novel putative low-affinity insulin-like growth factor factor- binding protein, LIBC (Lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999;5:2511-19.
  60. Venturini M, Catzeddu T, Del Mastro L, et al. Erlotinib given sequentially to capecitabine and vi- norelbine as first-line chemotherapy in metastatic breast cancer patients: A dose finding study. J Clin Oncol 2004;22:14s.
  61. Vogel CL, Burris HA, Limentani S, et al. A phase II study of trastuzumab-DMI, a HER2 antibody conjugate, in patients with HER2 metastatic breast cancer: Final results. J Clin Oncol 2009;27:15s.
  62. Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64:6652-59.
  63. Yarden Y, Sliwkowski MX.Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
  64. Yu K, Toral-Barza L, Discafani C, et al. MTOR, a novel target in breast cancer: The effect of CCI- 779, an mTOR inhibitor, in preclinical models of breast cancer Endocr Relat Cancer 2001;8:249-58.
  65. Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000;18:927-41.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах